Valuation: Ocular Therapeutix, Inc.

Market Cap 1.37B 1.24B 1.15B 1.03B 1.95B 129B 2.02B 13.76B 5.46B 68.82B 5.13B 5.02B 218B P/E 2026 *
-3.86x
P/E 2027 * -3.95x
Enterprise Value 997M 904M 836M 754M 1.42B 94.04B 1.47B 10.04B 3.98B 50.23B 3.74B 3.66B 159B EV / Sales 2026 *
19.6x
EV / Sales 2027 * 12.9x
Free-Float
99.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.11%
1 week-5.84%
Current month-10.90%
1 month-15.85%
3 months-38.15%
6 months-32.21%
Current year-48.85%
1 week 6
Extreme 5.995
6.87
1 month 6
Extreme 5.995
7.54
Current year 6
Extreme 5.995
13.03
1 year 6
Extreme 5.995
16.44
3 years 2.05
Extreme 2.05
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer - 28/09/2021
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 A Sell

General Counsel

-11,984 0.0057%
10/2/26 A Sell

Executive/Senior Manager

-9,990 0.0047%
10/2/26 A Sell

Chief Technology Officer

-10,869 0.0051%
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%-5.84%-45.04%+176.00% 1.37B
+1.26%+6.61%+40.79%+145.27% 1,286B
+0.79%+3.45%+45.84%+92.04% 688B
+0.20%+1.28%+26.97%+114.41% 521B
+0.43%+3.69%+41.45%+70.04% 386B
+0.55%+0.70%+59.02%+45.79% 364B
+1.13%+0.74%+28.39%+60.32% 302B
+0.21%+0.37%+3.33%+38.57% 287B
-0.30%+1.14%+38.29%+70.56% 252B
+0.08%+0.71%+34.44%+123.99% 208B
Average +0.31%+1.29%+27.35%+93.70% 430B
Weighted average by Cap. +0.68%+3.25%+37.67%+99.31%

Financials

2026 *2027 *
Net sales 50.9M 46.12M 42.66M 38.49M 72.54M 4.8B 75.1M 512M 203M 2.56B 191M 187M 8.14B 91.18M 82.63M 76.43M 68.96M 130M 8.6B 135M 918M 364M 4.59B 342M 335M 14.58B
Net income -362M -328M -303M -274M -516M -34.14B -534M -3.65B -1.45B -18.24B -1.36B -1.33B -57.89B -380M -344M -319M -287M -542M -35.84B -561M -3.83B -1.52B -19.15B -1.43B -1.4B -60.77B
Net Debt -369M -334M -309M -279M -526M -34.79B -544M -3.72B -1.47B -18.59B -1.38B -1.36B -59B -193M -175M -162M -146M -275M -18.22B -285M -1.95B -772M -9.73B -725M -710M -30.89B
Projected Income Statement - Annual - Ocular Therapeutix, Inc.
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
13/11/26 $6.210 -1.11% 2,488,600
12/11/26 $6.280 -5.71% 2,337,461
11/11/26 $6.660 +0.76% 2,989,841
10/11/26 $6.610 -3.50% 2,657,851
09/11/26 $6.850 +3.87% 3,556,073
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ocular Therapeutix, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.210USD
Average target price
25.73USD
Spread / Average Target
+314.29%
  1. Stock Market
  2. Stocks
  3. OCUL Stock